v3.26.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2026
Dec. 31, 2025
Current assets:    
Cash and cash equivalents $ 16,160 $ 10,743
Available-for-sale investments 41,258 67,944
Other receivables 426 873
Prepaid expenses 518 677
Total current assets 58,362 80,237
Restricted cash 1,495 2,235
Property and equipment, net 4,127 4,263
Operating lease, right-of-use assets 5,353 5,524
Financing lease, right-of-use assets 298 596
Other assets 190 148
Total assets 69,825 93,003
Current liabilities:    
Accounts payable 3,242 3,891
Accrued expenses 6,690 9,791
Current portion of operating lease liability 946 836
Current portion of financing lease liability 518 630
Total current liabilities 11,396 15,148
Long-term operating lease liability, net of current portion 9,799 10,308
Long-term financing lease liability, net of current portion 36 259
Commitments and contingencies (Note 4)
Stockholders’ equity:    
Preferred stock, $0.001 par value per share; 5,000,000 undesignated authorized shares as of June 30, 2026 (unaudited) and December 31, 2025, respectively; no shares issued or outstanding as of June 30, 2026 (unaudited) and December 31, 2025
Common stock, $0.001 par value per share:; 340,000,000 authorized shares as of June 30, 2026 (unaudited) and December 31, 2025; issued and outstanding shares - 98,087,425 as of June 30, 2026 (unaudited) and 98,031,104 as of December 31, 2025 98 98
Additional paid-in capital 676,022 673,554
Accumulated other comprehensive loss (68) (8)
Accumulated deficit (627,264) (606,164)
Total aTyr Pharma stockholders’ equity 48,788 67,480
Noncontrolling interest in Pangu BioPharma Limited (194) (192)
Total stockholders' equity 48,594 67,288
Total liabilities and stockholders’ equity $ 69,825 $ 93,003